HilleVax Announces Immunogenicity Results For Run-In Cohort Of NEST-IN1 Phase 2b Clinical Trial Of HIL-214 Norovirus Vaccine Candidate
HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results from a prespecified immunogenicity analysis of the 203 subjects